| Literature DB >> 31671845 |
Susana Santos1,2, Tiago Ferreira3,4, José Almeida5,6, Maria J Pires7,8, Aura Colaço9,10, Sílvia Lemos11,12, Rui M Gil da Costa13,14,15, Rui Medeiros16,17,18,19, Margarida M S M Bastos20, Maria J Neuparth21, Helena Abreu22, Rui Pereira23, Mário Pacheco24, Isabel Gaivão25, Eduardo Rosa26,27, Paula A Oliveira28,29.
Abstract
Some diet profiles are associated with the risk of developing cancer; however, some nutrients show protective effects. Porphyra umbilicalis is widely consumed, having a balanced nutritional profile; however, its potential for cancer chemoprevention still needs comprehensive studies. In this study, we incorporated P. umbilicalis into the diet of mice transgenic for the human papillomavirus type 16 (HPV16), which spontaneously develop pre-malignant and malignant lesions, and determined whether this seaweed was able to block lesion development. Forty-four 20-week-old HPV+/- and HPV-/- mice were fed either a base diet or a diet supplemented with 10% seaweed. At the end of the study, skin samples were examined to classify HPV16-induced lesions. The liver was also screened for potential toxic effects of the seaweed. Blood was used to study toxicological parameters and to perform comet and micronucleus genotoxicity tests. P. umbilicalis significantly reduced the incidence of pre-malignant dysplastic lesions, completely abrogating them in the chest skin. These results suggest that P. umbilicalis dietary supplementation has the potential to block the development of pre-malignant skin lesions and indicate its antigenotoxic activity against HPV-induced DNA damage. Further studies are needed to establish the seaweed as a functional food and clarify the mechanisms whereby this seaweed blocks multistep carcinogenesis induced by HPV.Entities:
Keywords: K14HPV16; cancer; genotoxicity assay; papillomavirus
Mesh:
Year: 2019 PMID: 31671845 PMCID: PMC6891340 DOI: 10.3390/md17110615
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Relative weight of organs in the experimental groups (mean ± standard error).
| Liver | Right Kidney | Left Kidney | Spleen | Lung | Heart | Bladder | Thymus | |
|---|---|---|---|---|---|---|---|---|
| Group I (HPV16−/−, | 0.0541 ± 0.0049 | 0.0060 ± 0.0002 | 0.0058 ± 0.0003 | 0.0040 ± 0.0002 | 0.0052 ± 0.0002 1 | 0.0037 ± 0.0002 | 0.0006 ± 0.0001 | 0.0010 ± 0.0001 |
| Group II (HPV16+/−, | 0.0670 ± 0.0015 | 0.0067 ± 0.0002 | 0.0065 ± 0.0001 | 0.0063 ± 0.0007 | 0.0063 ± 0.0003 | 0.0046 ± 0.0002 | 0.0010 ± 0.0001 | 0.0011 ± 0.0001 |
| Group III (HPV16−/−, base diet) | 0.0574 ± 0.0012 | 0.0057 ± 0.0002 | 0.0062 ± 0.0002 | 0.0047 ± 0.0002 | 0.0063 ± 0.0003 | 0.0042 ± 0.0002 | 0.0003 ± 0.0002 | 0.0012 ± 0.0002 |
| Group IV (HPV16+/−, base diet) | 0.0717 ± 0.0019 | 0.0069 ± 0.0002 | 0.0068 ± 0.0002 | 0.0083 ± 0.0010 | 0.0071 ± 0.0002 | 0.0051 ± 0.0002 | 0.0008 ± 0.0001 | 0.0014 ± 0.0001 |
1p = 0.016 statistically different from group III.
Incidence of histological lesions in skin chest and ear samples in the experimental groups.
| Skin Chest Incidence/ | Ear Incidence/ | |||||
|---|---|---|---|---|---|---|
| Normal | Epidermal Hyperplasia | Epidermal Dysplasia | Normal | Epidermal Hyperplasia | Epidermal Dysplasia | |
| Group I (HPV16−/−, | 11/11 | 0/11 | 0/11 | 11/11 | 0/11 | 0/11 |
| Group II (HPV16+/−, | 0/11 | 11/11 | 0/11 | 0/11 | 7/9 | 2/9 |
| Group III (HPV16−/−, base diet) | 11/11 | 0/11 | 0/11 | 11/11 | 0/11 | 0/11 |
| Group IV (HPV16+/−, base diet) | 0/11 | 4/11 1 | 7/11 | 0/11 | 4/11 | 7/11 |
1p = 0.004, statistically different from group II.
Figure 1Skin histology samples of female FVB/n mice, magnification 200×, hematoxylin and eosin (H&E) staining: (a) Normal skin histology in wild-type groups (I and III); (b) Epidermal hyperplasia in K14human papillomavirus(HPV)16 transgenic mice; (c) Epidermal dysplasia in K14HPV16 transgenic mice.
Serum biochemical parameters (mean ± standard error).
| Group I (HPV16−/− | Group II (HPV16+/−, | Group III (HPV16−/− Base Diet) | Group IV (HPV16+/− Base Diet) | |
|---|---|---|---|---|
| Albumin (g/L) | 28.65 ± 1.37 | 30.43 ± 0.93 | 29.78 ± 1.71 | 30.37 ± 0.96 |
| Total proteins (g/L) | 45.95 ± 1.72 | 50.32 ± 2.24 | 51.34 ± 4.07 | 49.62 ± 1.12 |
| Glucose (mg/dL) | 222.29 ± 11.16 | 197.65 ± 15.97 | 195.70 ± 15.99 | 198.07 ± 13.36 |
| Aspartate aminotransferase (U/L) | 35.63 ± 4.03 | 40.89 ± 5.65 | 37.28 ± 4.70 | 38.85 ± 3.54 |
| Alanine aminotransferase (U/L) | 59.34 ± 5.17 | 65.66 ± 7.16 | 44.74 ± 3.76 | 51.82 ± 3.70 |
| Gamma glutamyltransferase (U/L) | 31.75 ± 3.17 | 40.07 ± 7.67 | 48.61 ± 6.11 | 60.78 ± 8.35 |
Figure 2Mean values of non-specific genetic damage index (GDI, grey) and oxidative genetic damage index resulted from the assay with an extra step of digestion with formamidopyrimidine DNA glycosilase (FPG, GDIFPG, black), measured in peripheral blood cells of female FVB/n mice (n = 11 for each group). Asterisk (‘*’) represents statistically significant differences (p = 0.006) relative to non-specific DNA damage (grey) in group II, in comparison to the control group IV (grey). Bars represent the standard deviation.
Figure 3Values of net FPG-sensitive sites from the comet assay with an additional FPG step to detect oxidized purine bases. ‘*’ represents statistically significant difference (p = 0.001) in group I, in relation to group III; ’**’ represents statistically significant difference (p < 0.001) in group II, in relation to group IV (n = 11 for each group).
Figure 4Mean frequency of micronuclei in 1000 erythrocytes of female mice FVB/n during the experimental study (n = 22 for each group). Bars represent the standard deviation.